BACKGROUND:Cytidine diphosphate choline (citicoline) has been previously shown to have efficacy in reducing the functional impairments associated with acute stroke. Citicoline is thought to have neuroprotective benefits and has been used for the treatment of chronic cerebrovascular disorders, though its effectiveness has not been fully tested. This randomized, double-blind clinical trial was conducted to determine whether daily citicoline treatment improves neurocognitive and neuroimaging outcome over 12 months among patients diagnosed with vascular dementia (VaD). METHODS:30 patients diagnosed with VaD, based upon NINDS-AIREN and DSM-IV criteria, were randomized and treated with either 500 mg of citicoline or placebo twice per day. Patients were assessed at baseline, and at 6, and 12 months on a battery of neurocognitive tests. Neuroimaging measures of total brain volume and subcortical/periventricular hyperintensity (SH) volume on magnetic resonance imaging (MRI) were collected at baseline and the 12-month follow-up. RESULTS: The citicoline and placebo treatment groups did not differ in their neuropsychological performance at baseline and the 12-month follow-up. Significant declines in neuropsychological performance were noted, as well as significantly increased SH and reduced total brain volumes on MRI for both groups at the 12-month follow-up. CONCLUSIONS: The efficacy of long-term citicoline treatment for cognitive impairment and neuropathological decline in those patients already meeting criteria for VaD does not appear to be substantiated by the current study. Copyright 2003 S. Karger AG, Basel
RCT Entities:
BACKGROUND:Cytidine diphosphate choline (citicoline) has been previously shown to have efficacy in reducing the functional impairments associated with acute stroke. Citicoline is thought to have neuroprotective benefits and has been used for the treatment of chronic cerebrovascular disorders, though its effectiveness has not been fully tested. This randomized, double-blind clinical trial was conducted to determine whether daily citicoline treatment improves neurocognitive and neuroimaging outcome over 12 months among patients diagnosed with vascular dementia (VaD). METHODS: 30 patients diagnosed with VaD, based upon NINDS-AIREN and DSM-IV criteria, were randomized and treated with either 500 mg of citicoline or placebo twice per day. Patients were assessed at baseline, and at 6, and 12 months on a battery of neurocognitive tests. Neuroimaging measures of total brain volume and subcortical/periventricular hyperintensity (SH) volume on magnetic resonance imaging (MRI) were collected at baseline and the 12-month follow-up. RESULTS: The citicoline and placebo treatment groups did not differ in their neuropsychological performance at baseline and the 12-month follow-up. Significant declines in neuropsychological performance were noted, as well as significantly increased SH and reduced total brain volumes on MRI for both groups at the 12-month follow-up. CONCLUSIONS: The efficacy of long-term citicoline treatment for cognitive impairment and neuropathological decline in those patients already meeting criteria for VaD does not appear to be substantiated by the current study. Copyright 2003 S. Karger AG, Basel
Authors: Angela L Jefferson; Deborah Cahn-Weiner; Patricia Boyle; Robert H Paul; David J Moser; Norman Gordon; Ronald A Cohen Journal: Int J Geriatr Psychiatry Date: 2006-08 Impact factor: 3.485
Authors: William D S Killgore; Amy J Ross; Toshikazu Kamiya; Yoko Kawada; Perry F Renshaw; Deborah A Yurgelun-Todd Journal: Int J Eat Disord Date: 2010-01 Impact factor: 4.861
Authors: Elizabeth M Lane; Robert H Paul; David J Moser; Thomas D Fletcher; Ronald A Cohen Journal: J Int Neuropsychol Soc Date: 2011-05 Impact factor: 2.892
Authors: Genevieve Z Steiner; Danielle C Mathersul; Freya MacMillan; David A Camfield; Nerida L Klupp; Sai W Seto; Yong Huang; Mark I Hohenberg; Dennis H Chang Journal: Evid Based Complement Alternat Med Date: 2017-02-19 Impact factor: 2.629